Lurasidone Hydrochloride

+ 38 more variants

• Insomnia: Some patients may find it difficult to fall or stay asleep.
• Vomiting: More severe than simple nausea, this may require a dose adjustment.
• Increased Salivation: A noticeable increase in saliva production or drooling.
• Dystonia: Sudden, involuntary muscle contractions, often in the neck, jaw, or tongue.
• Weight Gain: While lurasidone is considered 'weight-neutral' compared to other antipsychotics, some patients may still experience a modest increase in weight.

• Hyperprolactinemia: An increase in the hormone prolactin, which can lead to breast swelling, nipple discharge, or changes in menstrual periods.
• Dyslipidemia: Changes in cholesterol or triglyceride levels.
• Tardive Dyskinesia (TD): A potentially irreversible condition involving repetitive, involuntary movements, typically of the face, tongue, or jaw. The risk of TD increases with the duration of treatment and the cumulative dose.

> Warning: Stop taking Lurasidone and call your doctor immediately if you experience any of these serious reactions.

• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction characterized by high fever, stiff muscles, confusion, sweating, and changes in heart rate or blood pressure. This is a medical emergency.
• Severe Allergic Reactions: Symptoms include rash, itching, hives, and swelling of the face, lips, or throat (angioedema).
• Seizures: Lurasidone can lower the seizure threshold, especially in patients with a history of epilepsy.
• High Blood Sugar (Hyperglycemia): In extreme cases, this can lead to ketoacidosis or coma. Symptoms include extreme thirst, frequent urination, and fruity-smelling breath.
• Low White Blood Cell Count: A significant drop in infection-fighting cells (leukopenia or neutropenia) can occur, making you more susceptible to infections.

With prolonged use, patients should be monitored for metabolic changes. Although lurasidone has a lower risk than some other medications, long-term use can still contribute to the development of Type 2 Diabetes or cardiovascular issues. Regular monitoring of weight, blood glucose, and lipid profiles is recommended. Additionally, the risk of Tardive Dyskinesia is a primary concern with long-term antipsychotic therapy; healthcare providers should perform regular 'AIMS' (Abnormal Involuntary Movement Scale) exams to catch early signs of this condition.

Lurasidone carries two critical FDA Black Box Warnings—the most serious type of warning issued by the FDA.

1. 1Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.
2. 2Suicidal Thoughts and Behaviors: Antidepressants and some antipsychotics used for depression can increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24). Patients of all ages starting lurasidone for bipolar depression should be monitored closely for worsening of symptoms or the emergence of suicidal ideation.

Report any unusual symptoms or changes in mood to your healthcare provider immediately.

Major Precautions

• Cerebrovascular Adverse Reactions: In clinical trials of elderly patients with dementia, there was a higher incidence of stroke and transient ischemic attacks (TIAs) in those taking antipsychotics.
• Neuroleptic Malignant Syndrome (NMS): This is a potentially fatal symptom complex. If a patient develops high fever and muscle rigidity, the medication must be discontinued immediately.
• Tardive Dyskinesia: The risk of developing involuntary movements increases with the length of treatment. If signs of TD appear, the healthcare provider may consider stopping the medication.
• Metabolic Changes: Atypical antipsychotics are associated with metabolic changes, including high blood sugar (hyperglycemia), high cholesterol (dyslipidemia), and weight gain. Regular blood tests are required.
• Orthostatic Hypotension and Syncope: Lurasidone may cause a sudden drop in blood pressure when standing up, which can lead to dizziness or fainting. This is most common when first starting the drug or increasing the dose.
• Hyperprolactinemia: Like other D2 antagonists, lurasidone can elevate prolactin levels, which may affect reproductive function and bone density over time.

To ensure safety, your healthcare provider will likely require the following tests:

• Blood Glucose: To monitor for the development of diabetes.
• Lipid Panel: To check cholesterol and triglyceride levels.
• Weight/BMI: Monitored at every visit.
• CBC (Complete Blood Count): To ensure white blood cell counts remain within a safe range.
• AIMS Exam: A physical assessment for involuntary movements.

Lurasidone can cause significant somnolence (drowsiness) and may impair judgment, thinking, and motor skills. Patients should not drive, operate heavy machinery, or engage in dangerous activities until they are certain the medication does not affect them in these ways.

Alcohol should be avoided while taking lurasidone. Alcohol can worsen the sedative effects of the medication and increase the risk of respiratory depression and impaired motor coordination.

If you and your doctor decide to stop lurasidone, the dose should be tapered (gradually reduced) rather than stopped suddenly. Abruptly stopping can cause 'rebound' psychosis or symptoms like nausea, sweating, and insomnia.

> Important: Discuss all your medical conditions, especially heart problems, diabetes, or a history of seizures, with your healthcare provider before starting Lurasidone.

• Antihypertensive Agents: Because lurasidone can cause orthostatic hypotension (dizziness upon standing), taking it with blood pressure medications may increase the risk of fainting and falls.
• Dopamine Agonists: Drugs used for Parkinson’s disease (like levodopa) work by increasing dopamine, while lurasidone works by blocking it. These drugs can cancel each other out, worsening both conditions.

• Grapefruit and Grapefruit Juice: Grapefruit is a potent inhibitor of the CYP3A4 enzyme. Consuming grapefruit while taking lurasidone can lead to dangerously high levels of the drug in your system. It is best to avoid grapefruit products entirely.
• High-Calorie Requirement: As noted previously, lurasidone requires at least 350 calories for absorption. Failure to meet this requirement is a 'negative interaction' that results in sub-therapeutic drug levels.

• St. John’s Wort: This herbal supplement is a strong inducer of CYP3A4. Taking it with lurasidone can significantly reduce the medication's effectiveness, potentially leading to a relapse of psychiatric symptoms.
• Kava, Valerian, and Melatonin: These supplements have sedative properties and may increase the drowsiness caused by lurasidone.

Lurasidone does not typically interfere with common laboratory tests, but it can cause physiological changes that show up on labs, such as:

• False Positives for Urine Drug Screens: Some antipsychotics have been known to cause false positives for methadone or amphetamines, though this is less common with lurasidone than with other agents.
• Prolactin Elevation: Can be seen on hormone blood tests.

For each major interaction, the mechanism usually involves the liver's metabolic pathways. When lurasidone levels are too high, the clinical consequence is an increased risk of movement disorders and sedation. When levels are too low, the consequence is a lack of symptom control. Management strategies always involve dose titration or choosing alternative medications under strict medical supervision.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines or vitamins.

These are conditions where the drug should be used only if the benefits clearly outweigh the risks, and with extreme caution.

• Elderly Patients with Dementia: Due to the increased risk of death and stroke, lurasidone is generally avoided in this population unless no other options exist and the psychiatric symptoms are severe.
• Severe Hepatic or Renal Impairment: While not an absolute contraindication, these conditions require significant dose reductions and frequent monitoring.
• History of Seizures: Lurasidone can lower the threshold for seizures. It should be used cautiously in patients with epilepsy or conditions that predispose them to seizures (e.g., head trauma).
• Cardiovascular Disease: Patients with a history of heart attack, heart failure, or conduction abnormalities (like QT prolongation) require careful monitoring because lurasidone can cause orthostatic hypotension.

While lurasidone is chemically distinct, patients who have had severe reactions to other benzoisothiazol derivatives (such as ziprasidone) should be monitored closely, as there is a theoretical risk of cross-sensitivity, though this is not well-documented in clinical literature.

> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to psychiatric medications, before prescribing Lurasidone.

Lurasidone is FDA-approved for:

• Schizophrenia: Children aged 13 to 17 years.
• Bipolar Depression: Children aged 10 to 17 years.

The safety and effectiveness of lurasidone in children under 10 years of age have not been established. In pediatric trials, the side effect profile was generally similar to that seen in adults, though there was a slightly higher incidence of weight gain and somnolence in younger patients.

Clinical studies of lurasidone did not include sufficient numbers of patients aged 65 and over to determine if they respond differently than younger patients. However, geriatric patients are generally more sensitive to the side effects of antipsychotics, particularly:

• Fall Risk: Due to sedation and orthostatic hypotension.
• Tardive Dyskinesia: Elderly women are at the highest risk for this movement disorder.
• Renal Clearance: Many elderly patients have reduced kidney function, which necessitates lower starting doses.

In patients with moderate (CrCl 30-50 mL/min) and severe (CrCl < 30 mL/min) renal impairment, the body's ability to clear lurasidone is reduced.

• Dose Adjustment: The starting dose should be 20 mg, and the dose should not exceed 80 mg per day. Lurasidone has not been extensively studied in patients on hemodialysis.

• Moderate Impairment (Child-Pugh 7-9): The dose should be capped at 80 mg.
• Severe Impairment (Child-Pugh 10-15): The dose should be capped at 40 mg.
• Mechanism: Since the liver is the primary site of metabolism, impairment leads to higher blood levels of the drug, increasing the risk of adverse effects.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the medication remains safe and effective over time.

The onset of action for lurasidone typically occurs within 1 to 2 weeks for initial symptom improvement, though the full therapeutic effect may take 4 to 6 weeks. It does not appear to cause significant QT prolongation (a heart rhythm issue) at therapeutic doses, which is a safety advantage over some other antipsychotics like ziprasidone.

| Parameter | Value |

|---|---|

| Bioavailability | 9% - 19% (Highly food-dependent) |

| Protein Binding | ~99% (Albumin and AAG) |

| Half-life | ~18 hours |

| Tmax | 1 - 3 hours |

| Metabolism | Hepatic (Primary CYP3A4) |

| Excretion | Fecal 80%, Renal 9% |

• Molecular Formula: C28H36N4O2S · HCl
• Molecular Weight: 529.14 g/mol
• Solubility: Very slightly soluble in water; soluble in methanol.
• Structure: It is a benzoisothiazol derivative characterized by a piperazine-based side chain and a bicyclic ring system.

Lurasidone is classified as an atypical (second-generation) antipsychotic. It is related to other medications in this class, such as aripiprazole, quetiapine, and risperidone, but is distinguished by its specific 5-HT7 receptor affinity and its metabolic-friendly profile.